Sex difference in fibrin clot lysability: Association with coronary plaque composition

Ramanathan, Ramshanker; Gram, Jørgen Brodersen; Sidelmann, Johannes Jakobsen; Dey, Damini; Kusk, Martin Weber; Nørgaard, Bjarne Linde; Sand, Niels Peter Rønnow

doi:10.1016/j.thromres.2018.12.020

Cited by 13 publications

(5 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…↓ in CAD vs healthy controls [95,96] and cardiac transplant recipients with CAD vs no CAD [73] Global fibrinolytic capacity a ↓ in CAD vs healthy controls [97] a Plasma + tPA added to standardized fibrin tablet, fibrin D-dimer generation measured.…”

Section: Global or Dynamic Assaysmentioning

confidence: 99%

Fibrin clot properties in coronary artery disease: new determinants and prognostic markers

Larsen¹,

Hvas²

2021

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

Despite improved diagnosis and treatment options, coronary artery disease (CAD) is still a leading cause of mortality and morbidity worldwide. Established risk factors as smoking, hypercholesterolemia, and hypertension only partly explain the pathophysiology of CAD.Besides the well-known role of platelets in atherosclerosis and arterial thrombus formation, reduced endogenous fibrinolytic activity may play a key role for CAD formation and progression. Thus, biomarkers of fibrinolysis may be future CAD risk markers. In this review we provide an overview of regulators of fibrinolysis and the main factors of importance to fibrin clot formation including coagulation factor XIII, thrombin and fibrinogen. We summarize markers of altered fibrinolysis and current laboratory methods applied in clinical practice and research. We present today's evidence on fibrin clot properties in patients with stable CAD or acute coronary syndrome compared to healthy individuals and the significance of altered fibrinolysis as a risk for coronary thrombotic disease. In conclusion, we find evidence that altered fibrin clot properties and impaired fibrinolysis appears to contribute significantly to the thromboembolic risk in CAD patients. Therefore, more research is crucial in order to clarify whether modulation of the fibrinolytic system may pave the way for improved treatment of CAD.

show abstract

Section: Global or Dynamic Assaysmentioning

confidence: 99%

Fibrin clot properties in coronary artery disease: new determinants and prognostic markers

Larsen¹,

Hvas²

2021

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…However, some earlier studies concluded that the stock volatility had larger effects on elderly population. 34,35 This difference may be due to the different population characteristics and relatively small sample size in prior investigations. Similar to a recent study conducted in China, 10 our study indicated larger effect estimates among females, which might be partly explained by reduced fibrin clot lysability of coronary plaques for women compared with men.…”

Section: Discussionmentioning

confidence: 99%

Stock volatility may trigger the onset of acute coronary syndrome: A nationwide case-crossover analysis

Zhu,

Chen,

Liu

et al. 2023

TIME

View full text Add to dashboard Cite

<p>Stock volatility, an adverse psychological stressor, has been linked to cardiovascular mortality or hospitalization. However, no studies had quantified the risk of acute coronary syndrome (ACS) onset from stock market fluctuation. Using the time-stratified case-crossover design, which could control for the potential confounding from time-invariant, we conducted the analysis based on a nationwide registry comprising of 2,113,728 ACS patients in China from January, 2015 to December, 2021. We obtained daily returns (%) of three main stock indexes in Chinese Mainland, and matched the case and control days of ACS onset on hourly level. The data were analyzed using conditional logistic regression models. The associations between daily stock returns and ACS onset were U-shaped with stock rise and fall both increasing the risk of ACS onset. The excess risks associated with each 1%-decrease of daily stock returns for Shanghai, Shenzhen and ChiNext index were 0.96% (95%CI: 0.40,1.51), 0.65% (95%CI: 0.27,1.03) and 0.87% (95%CI: 0.52,1.21) at the concurrent day, respectively; and a 1%-increase of daily stock returns was associated with 1.06% (95%CI: 0.61,1.52), 0.45% (95%CI: 0.11,0.80) and 0.17% (95%CI: -0.08,0.41) increases of ACS onset, respectively. Thereafter, most of the associations gradually attenuated, disappeared after 3 days. The associations were significant for unstable angina and ST-segment-elevation myocardial infarction, but not for non-ST-segment-elevation myocardial infarction. This nationwide study provides novel and robust evidence that both stock rise and fall could increase the risk of ACS onset, highlighting the importance of heart care and psychological support during fluctuations of stock market.</p>

show abstract

“…были изучены кинетика полимеризации фибрина, свойства фибриновых нитей, лизис фибринового сгустка и их различия у мужчин и женщин с ФП. У женщин наблюдались более высокие показатели латеральной агрегации протофибрилл во время полимеризации фибрина (p<0,04) и менее интенсивный фибринолиз в сравнении с мужчинами, что говорит о меньшей активности системы фибринолиза и более агрессивной полимеризации фибрина у женщин [36,37]. Более высокая плотность фибринового сгустка по данным ТД согласуется с известным представлением о повышенном протромботическом профиле у женщин в сравнении с мужчинами.…”

Section: Discussionunclassified

Thrombodynamics Test in Assessing the Risk of Thrombus Formation in Patients with Atrial Fibrillation Taking Direct Oral Anticoagulants

Gebekova

Ivanov

Asambaeva

et al. 2022

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Aim. To evaluate thrombus characteristics in patients with atrial fibrillation (AF) taking different direct oral anticoagulants (DOACs) using Thrombodynamics test.Materials and methods. Thrombodynamics test was performed in 100 patients with paroxysmal and permanent forms of AF taking different DOACs, dose choice was done in accordance with the instructions for drugs use. For analysis samples of fresh citrated platelet-free plasma were taken just before regular DOACs dose intake (trough concentration). Statistical data processing was carried out using R software packages.Results. All patients had no history of thrombosis or bleeding before inclusion in this study. All parameters of Thrombodynamics test taken at residual concentration of DOACs were in general within reference values, that is in the area of normal coagulation: spatial clot growth rate (V) – 26.56 (25.0; 29.2) μm/min, the time to the start of clot growth (Tlag) – 1.05 (0.85; 1.27) min, initial spatial clot growth rate (Vi) – 44.3±7.7 μm/min, stationary spatial clot growth rate (Vst) – 26.5 (24.9; 28.4) μm/min, clot size (CS) – 999.7 (912.9; 1084.7) μm, clot density (D) – 22883.1±3199.9 arb. units. D was appeared to be higher in women [22947.7 (21477.5; 22947.7) vs men [22124.8 (19722.8; 22124.8), p=0.035] and Tlag was significantly higher in patients with chronic heart failure [1.2 (1.0; 1.2) vs 1.0 (0.8; 1.0), p=0.008]. A correlation was found between level of creatinine and Tlag parameter, glomerular filtration rate (GFR) and clot density. With an increase in the level of creatinine in the blood and a decrease in GFR, respectively, there was an increase in Tlag parameter (p-value 0.038); with an increase in GFR, clot density decrease (p-value 0.005).Conclusion. All parameters of Thrombodynamics test on residual concentration of DOACs were within reference values that indicated optimal anticoagulant effect of all DOACs. The obtained data of normal coagulation at the residual concentration of the anticoagulant are consistent with the previously obtained data on the safety and effectiveness of DOACs using other methods. Further studies with clinical end points are needed to assess the clinical value of this method.

show abstract

Sex difference in fibrin clot lysability: Association with coronary plaque composition

Cited by 13 publications

References 52 publications

Fibrin clot properties in coronary artery disease: new determinants and prognostic markers

Fibrin clot properties in coronary artery disease: new determinants and prognostic markers

Stock volatility may trigger the onset of acute coronary syndrome: A nationwide case-crossover analysis

Thrombodynamics Test in Assessing the Risk of Thrombus Formation in Patients with Atrial Fibrillation Taking Direct Oral Anticoagulants

Contact Info

Product

Resources

About